ArticleJournal of cardiothoracic surgery2024
Taurolidine-containing solution for reducing cardiac implantable electronic device infection-early report from the European TauroPace™ registry.
Article in Journal of cardiothoracic surgery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04735666 (European TauroPace Registry - University of Schleswig-Holstein Prospective Observational Clinical Study), which is not on this map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
European TauroPace Registry - University of Schleswig-Holstein Prospective Observational Clinical Study
Who cites it
6 citing papers in PubMed.
- Trends in cardiac implantable electronic device infections: 2015 to 2019.BMC cardiovascular disorders · 2026Article
- First-in-Human Intramediastinal Taurolidine Irrigation forJournal of cardiovascular development and disease · 2026Article
- Delphi consensus recommendations for preventing and treating cardiac implantable electronic device infections beyond current guidelines.Scientific reports · 2026Article
- Current Management of Infective Endocarditis: A Narrative Review Focused on Unmet Clinical Needs and the Multidisciplinary Approach.Journal of cardiovascular development and disease · 2026Review
- Antimicrobial Efficacy of a Taurolidine-Based Antimicrobial Compound on Contaminated Surfaces Simulated in a Standardized 4-Field Test.Advanced healthcare materials · 2026Article
- Efficacy of topical application of taurolidine 2% in promoting second intention healing of poststernotomy deep incisional wound infection.General thoracic and cardiovascular surgery cases · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionInfection is a significant complication of cardiac implantable electronic device (CIED) therapy. The European TauroPace™ Registry investigates the safety and efficacy of TauroPace™ (TP), an antimicrobial solution containing taurolidine, designed to prevent CIED infections.
methodsThis multicenter study included patients undergoing CIED procedures at participating centers where TP was used as a disinfectant for external hardware surfaces and an antiseptic for irrigating surgical sites. All patients eligible for CIED placement with adjunctive TP as the standard of care were included. Other aspects of CIED procedures adhered to current guidelines. Data on CIED-related infective endocarditis, CIED pocket infection, device and procedure-related complications, adverse events, and all-cause mortality were prospectively collected for 12 months. In cases of revision, the previous procedure was censored, and a new procedure was created. Binomial and Kaplan-Meier statistics were employed to analyze event rates.
resultsFrom January 2020 to November 2022, TP was used in 822 out of 1170 CIED procedures. Among patients who completed the 3-month follow-up, no CIED pocket infections were observed, and one case of CIED-related infective endocarditis was reported. In the 12-month follow-up cohort, two additional local pocket CIED infections were observed, resulting in a total of three major CIED infections within 1 year after the CIED placement procedure. The 3-month and 12-month major CIED infection rates were 0.125% and 0.51%, respectively. During the observation a complication rate of 4.4% was reported. No adverse events related to TP were observed.
conclusionsTP appears to be effective and safe in preventing CIED infections. CLINICALTRIALS: gov Identifier: NCT04735666.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.